endogenous reverse transcriptase inhibitors (ROME Therapeutics)

N/A

Report date: 2025/03/20 15:10:23
NME

Base Information

Drug Nameendogenous reverse transcriptase inhibitors (ROME Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsNerve DegenerationAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRome Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRome Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNerve DegenerationAutoimmune DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A